Klea Holding Reports Rebound and Targets Growth in Q4 2026

Klea Holding announced a revenue rebound in Q3 2026, primarily driven by its subsidiary, Smart Salem, experiencing strong demand in Wellness activities. The group expects further growth in Q4 2026 with the launch of Klea Pharmaceuticals and the debut of Smart Health in Riyadh, pending final approvals. Since hitting a low in March 2026, Smart Salem has seen a consistent month-on-month recovery. Q3 revenues showed a slight decline of 14% from the previous year but marked an improvement from a 20% drop earlier in 2026.

The Health Check-ups segment has been a growth catalyst, increasing by 36% at constant exchange rates. In response, Klea Holding launched the Klea Health brand, focusing on prevention and well-being. This initiative aims to expand services, including advanced health check-ups and longevity programs, leveraging existing infrastructure.

Looking ahead, Klea Holding anticipates that new revenue streams from Klea Pharmaceuticals and the strategic initiatives in the health sector will lead to a profitable 2026, matching last year's net profit figures.